An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature

Abstract

Abstract Alopecia areata is a common autoimmune disease, with a negative impact in health‐related quality of life, especially when affecting children and adolescents. Current medical therapies, mainly for severe disease, are not effective. There are no FDA (Food and Drug Administration)‐ or ANVISA (Agência Nacional de Vigilância Sanitária)‐approved therapy for children with alopecia areata. JAK inhibitors are emerging as a promising therapy.

Keywords

• adolescent
• alopecia areata
• dermatology
• hair loss
• JAK inhibitors
• tofacitinib